Mitsubishi UFJ Asset Management Co. Ltd. Sells 13,743 Shares of Hims & Hers Health, Inc. $HIMS

Mitsubishi UFJ Asset Management Co. Ltd. trimmed its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 24.4% during the 2nd quarter, HoldingsChannel reports. The firm owned 42,564 shares of the company’s stock after selling 13,743 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Hims & Hers Health were worth $2,122,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Signaturefd LLC grew its position in Hims & Hers Health by 17.7% during the first quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock valued at $76,000 after buying an additional 388 shares during the period. Ethic Inc. purchased a new position in shares of Hims & Hers Health during the 2nd quarter worth $348,000. Lake Hills Wealth Management LLC purchased a new position in shares of Hims & Hers Health during the 2nd quarter worth $277,000. Intellectus Partners LLC bought a new stake in shares of Hims & Hers Health during the 2nd quarter valued at $3,043,000. Finally, Occidental Asset Management LLC purchased a new stake in shares of Hims & Hers Health in the 2nd quarter worth $305,000. 63.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HIMS. Truist Financial decreased their target price on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a report on Monday, August 18th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $68.00 price objective on shares of Hims & Hers Health in a research note on Friday, September 12th. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. UBS Group set a $32.00 target price on shares of Hims & Hers Health in a report on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus target price of $45.27.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $36.00 on Friday. The firm has a market cap of $8.20 billion, a price-to-earnings ratio of 66.67, a price-to-earnings-growth ratio of 7.77 and a beta of 2.20. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The business has a 50-day moving average price of $50.86 and a 200-day moving average price of $51.16. Hims & Hers Health, Inc. has a twelve month low of $19.15 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. During the same period last year, the business posted $0.32 EPS. The firm’s revenue for the quarter was up 49.2% compared to the same quarter last year. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity

In other news, CFO Oluyemi Okupe sold 11,592 shares of Hims & Hers Health stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $57.13, for a total transaction of $662,250.96. Following the sale, the chief financial officer owned 70,232 shares in the company, valued at $4,012,354.16. This trade represents a 14.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Soleil Boughton sold 2,637 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $42.53, for a total transaction of $112,151.61. Following the transaction, the insider owned 155,856 shares of the company’s stock, valued at approximately $6,628,555.68. This represents a 1.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 712,336 shares of company stock worth $37,611,319 over the last quarter. Insiders own 13.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.